Transvection in Drosophila: trans-interaction between yellow enhancers and promoter is strongly suppressed by a cis-promoter only in certain genomic regions.

Transvection is a phenomenon of interallelic communication whereby enhancers of one allele can activate a promoter located on the homologous chromosome. It has been shown for many independent genes that enhancers preferentially act on the cis-linked promoter, but deletion of this promoter allows the enhancers to act in trans. Here, we tested whether this cis-preference in the enhancer-promoter interaction could be reconstituted outside of the natural position of a gene.

[The efficacy of an erythropoietin-calcitriol combination in patients with chronic kidney failure on programmed hemodialysis].

In 8 patients with chronic renal failure (CRF) on hemodialysis combined therapy (erythropoietin+calcitriol) effect was evaluated versus control group of 9 hemodialysis patients on erythropoietin monotherapy. In patients on the combined regimen the antianemic effect occurred sooner, this effect of calcitriol coming prior to correction of uremic defects in phosphoric-calcium metabolism. Calcitriol mechanisms of action in renal anemia and benefits of potential calcitriol+erythropoietin combination use in CRF patients suffering from uremic osteodystrophy, hypercatabolic conditions, uremic hypogonadism and infection complications are discussed.

[Calcitriol: role in the regulation of erythropoiesis, use in the treatment of renal anemia].

The efficiency of combined therapy (erythropoietin + calcitriol) used in 8 patients with chronic renal failure on programmed hemodialysis was comparatively evaluated with erythropoietin monotherapy employed in 9 patients with the same disease on hemodialysis which represented a control group. The anti-anemia effect was achieved on the average of 5 weeks earlier in the group of patients given the combined therapy than that in the controls. The differences between the two groups were statistically significant in the rate of anti-anemia effect achievement.

[Individual differences in the efficacy of Recormon in patients with terminal kidney failure. The role of iron deficiency].

Iron deficiency involvement in the results of long-term replacement therapy of renal anemia with recormon, a preparation of recombinant human erythropoietin, has been studied in chronic renal failure patients on programmed hemodialysis. The effect of recormon subcutaneous administration to 51 patients was found reduced in 9 patients; in 5 of them the decreased sensitivity to recormon was attributed to iron deficiency. During a year of treatment the percentage of iron-deficient patients rose from 9.